Paxil Litigation Update

GlaxoSmithKline PLC
15 January 2003

Issued: 15th January 2003, London

                            Paxil Litigation Update

     Trial for Hemi-Hydrate Patent Challenge to be Heard 5th February 2003

GlaxoSmithKline (GSK) today announced that the trial to hear arguments in the
Federal District Court of the Northern District of Illinois (Chicago) between
GSK and Apotex on GSK's patent covering the hemihydrate form of Paxil expiring
in 2006, will commence on 5th February 2003.

S M Bicknell
Company Secretary
15 January 2003

About GSK:

GlaxoSmithKline - one of the world's leading research-based pharmaceutical and
healthcare companies - is committed to improving the quality of human life by
enabling people to do more, feel better and live longer.

Under the safe harbor provisions of the US Private Securities Litigation Reform
Act of 1995, GlaxoSmithKline cautions investors that any forward-looking
statements or projections made by GSK, including those made in this news
release, are subject to risks and uncertainties that may cause actual results to
differ materially from those projected. Factors that may affect the company's
operations are discussed in the section "Cautionary factors that may affect
future results" in GSK's results announcement for the year ended 31 December
2001, filed with the U.S. Securities and Exchange Commission.

For company information, visit GSK on the World Wide Web at http://www.gsk.com

Enquiries:

UK Media enquiries:                                    Martin Sutton            [phone]
                                                       Siobhan Lavelle          [phone]

US Media enquiries:                                    Nancy Pekarek            [phone]
                                                       Mary Anne Rhyne          [phone]
                                                       Patricia Seif            [phone]

European Analyst/Investor enquiries:                   Duncan Learmouth         [phone]
                                                       Anita Kidgell            [phone]
                                                       Philip Thomson           [phone]

US Analyst/ Investor enquiries:                        Frank Murdolo            [phone]
                                                       Tom Curry                [phone]


                      This information is provided by RNS
            The company news service from the London Stock Exchange               BKKDDD